Christophe Louvet
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies 147
- Cancer Treatment and Pharmacology 73
- Pancreatic and Hepatic Oncology Research 63
- Colorectal Cancer Surgical Treatments 26
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis 43
- Pulmonary and Respiratory Medicine top 0.1%
- Gastric Cancer Management and Outcomes 55
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 34
- Pathology and Forensic Medicine top 0.2%
- Genetic factors in colorectal cancer 36
In The Last Decade
Christophe Louvet
265 papers receiving 17.3k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Oncology 14.9k
- Hepatology 3.6k
- Pulmonary and Respiratory Medicine 6.1k
- Cancer Research 2.5k
- Pathology and Forensic Medicine 2.4k
Countries citing papers authored by Christophe Louvet
This map shows the geographic impact of Christophe Louvet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Louvet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Louvet more than expected).
Fields of papers citing papers by Christophe Louvet
This network shows the impact of papers produced by Christophe Louvet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Louvet. The network helps show where Christophe Louvet may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Christophe Louvet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2023 | 5 | |
| 3 | 2023 | 0 | |
| 4 | Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Studybreakdown → | 2022 | 220 |
| 5 | 2022 | 2 | |
| 6 | 2021 | 71 | |
| 7 | 2021 | 7 | |
| 8 | 2020 | 2 | |
| 9 | 2019 | 70 | |
| 10 | 2014 | 8 | |
| 11 | 2011 | 64 | |
| 12 | 2011 | 27 | |
| 13 | 2009 | 262 | |
| 14 | KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximabbreakdown → | 2008 | 1141 |
| 15 | [Use of complementary medicine by cancer patients in a French oncology department]. | 2007 | 44 |
| 16 | KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab. | 2007 | 7 |
| 17 | 2004 | 70 | |
| 18 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Studybreakdown → | 2003 | 2290 |
| 19 | Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancerbreakdown → | 2000 | 3040 |
| 20 | 1986 | 4 |
About Christophe Louvet
Christophe Louvet is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine, having authored 278 papers that have together received 17.8k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (147 papers), Cancer Treatment and Pharmacology (73 papers), Pancreatic and Hepatic Oncology Research (63 papers), Gastric Cancer Management and Outcomes (55 papers), Hepatocellular Carcinoma Treatment and Prognosis (43 papers), Genetic factors in colorectal cancer (36 papers), Cancer Genomics and Diagnostics (34 papers) and Colorectal Cancer Surgical Treatments (26 papers). The work is most often cited by research in Oncology (14.9k citations), Hepatology (3.6k citations) and Pulmonary and Respiratory Medicine (6.1k citations). Christophe Louvet has collaborated with scholars based in France, Belgium and Canada. Frequent co-authors include Aimery de Gramont, Thierry André, Christophe Tournigand, Gérard Lledo, Olivier Bouché, F. Morvan, Bruno Landi, Pascal Hammel, Marc Buyse and Arié Figer. Their work appears in journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.